Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Down 5.70%
As of Friday, July 31, Dianthus Therapeutics, Inc.’s DNTH share price has dipped by 5.70%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Commentary & Analysis
Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Up 6.27%
As of Thursday, July 30, Dianthus Therapeutics, Inc.’s DNTH share price has surged by 6.27%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Up 5.63%
As of Friday, July 17, Dianthus Therapeutics, Inc.’s DNTH share price has surged by 5.63%, which has investors questioning if this is right time to sell.Michael Rose
Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Down 6.40%
As of Wednesday, July 01, Dianthus Therapeutics, Inc.’s DNTH share price has dipped by 6.40%, which has investors questioning if this is right time to buy.Michael Rose
Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Up 5.20%
As of Wednesday, June 24, Dianthus Therapeutics, Inc.’s DNTH share price has surged by 5.20%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | DNTH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,157.6 | $251.9 | 70% |
|
| Shares Out (Mil) | 48.0 | 50.8 | 47% |
|
| Institutional Ownership | 99.9% | 92.0% | 96% |
|
| Float (Mil) | 54.6 | 40.5 | 49% |
|
| Beta | 0.09 | 0.95 | 8% |
|
| Avg Daily Volume (000s) | 846 | 447 | 67% |
|
| Price Change (52-week) |
426.6% | 54.2% | 99% |
|
| Growth | DNTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | na | (9.8%) | na |
|
| EPS (5yr) | na | 16.3% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 9 | |
| Current EPS | ($0.909) | ($3.927) | ($4.651) | |
| Month Ago EPS | ($0.909) | ($3.927) | ($4.651) | |
| # Rev Up | 2 | 0 | 1 | |
| # Rev Down | 1 | 2 | 0 | |
| Three Months Ago EPS | ($1.111) | ($4.654) | ($5.114) | |
| Year/Year Chg | 6.9% | (6.6%) | 24.5% | |
| Financials | DNTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $39 | 2% |
|
| Net Income (TTM) (Mil) | ($174) | ($43) | 7% |
|
| EPS (TTM) | ($4.167) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($130) | ($30) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $618 | $3 | 93% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $5 | 17% |
|
| Enterprise Value (Q1) (Mil) | $3,719 | $182 | 58% |
|
| Valuation | DNTH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.12 | 2.60 | 79% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | DNTH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (21.8%) | (49.7%) | 20% |
|
| ROE | (22.7%) | (55.4%) | 23% |
|
| Liabilities to Assets | 3.7% | 30.3% | 2% |
|
| F-Score | 4 | 3 | 34% |
|
Dianthus Therapeutics, Inc. did not pass any screens on 7/30/2026.
